Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models

Journal of Controlled Release

Volumn 164, Issue 1, 2012, Pages 1-7

  Ishima, Yu ^a   Hara, Marie ^a   Kragh Hansen, Ulrich ^b   Inoue, Aki ^a   Suenaga, Ayaka ^a   Kai, Toshiya ^a,c   Watanabe, Hiroshi ^a   Otagiri, Masaki ^a,d   Maruyama, Toru ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b AARHUS UNIVERSITY   (Denmark)

^c Nipro Corporation   (Japan)

^d SOJO UNIVERSITY   (Japan)

Author keywords

Anticancer; HIF 1 ; Human serum albumin; Nitric oxide; p glycoprotein; S nitrosation

Indexed keywords

ANIMAL MODEL; ANTI-CANCER AGENTS; ANTICANCER; ANTICANCER EFFECTS; CASPASE-3; DOXORUBICIN; DRUG RESISTANCE; GUANYLATE CYCLASE; HUMAN SERUM ALBUMINS; IN-VITRO; IN-VIVO; K562 CELLS; LEUKEMIC CELLS; NO DONOR; P-GLYCOPROTEIN; PRO-APOPTOTIC EFFECTS; S-NITROSATION; SIGNALING PATHWAYS; TRAUT'S REAGENT; WESTERN BLOTS;

CELL DEATH; NITRATES;

NITRIC OXIDE;

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 8 BROMO CYCLIC GMP; ANTINEOPLASTIC AGENT; CYCLIC GMP; DOXORUBICIN; GLYCERYL TRINITRATE; GUANYLATE CYCLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MULTIDRUG RESISTANCE PROTEIN; NITRIC OXIDE; NITRIC OXIDE DONOR; RECOMBINANT HUMAN SERUM ALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NITROSATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL SURVIVAL; CYCLIC GMP; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; K562 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NITRIC OXIDE DONORS; NITROSO COMPOUNDS; P-GLYCOPROTEIN; SERUM ALBUMIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867767304     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.10.003     Document Type: Article

References (28)

1. L. Ignarro Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters Pharm. Res. 6 1989 651 659
2. N. Katayama, K. Nakajou, H. Komori, K. Uchida, J. Yokoe, N. Yasui, H. Yamamoto, T. Kai, M. Sato, T. Nakagawa, M. Takeya, T. Maruyama, and M. Otagiri Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug J. Pharmacol. Exp. Ther. 325 2008 69 76
3. N. Katayama, K. Nakajou, Y. Ishima, S. Ikuta, J. Yokoe, F. Yoshida, A. Suenaga, T. Maruyama, T. Kai, and M. Otagiri Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells Nitric Oxide 22 2010 259 265
4. D.R. Siemens, N. Hu, A.K. Sheikhi, E. Chung, L.J. Frederiksen, H. Pross, and C.H. Graham Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide Cancer Res. 68 2008 4746 4753
5. H. Yasuda Solid tumor physiology and hypoxia-induced chemo/radio- resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer Nitric Oxide 19 2008 205 216
6. B. Bonavida, S. Baritaki, S. Huerta-Yepez, M.I. Vega, D. Chatterjee, and K. Yeung Novel therapeutic applications of nitric oxide donors in cancer: roles in chemo- and immunosensitization to apoptosis and inhibition of metastases Nitric Oxide 19 2008 152 157
7. C. Riganti, E. Miraglia, D. Viarisio, C. Costamagna, G. Pescarmona, D. Ghigo, and A. Bosia Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res. 65 2005 516 525
8. R. Chen Removal of fatty acids from serum albumin by charcoal treatment J. Biol. Chem. 242 1967 173 181
9. T. Akaike, K. Inoue, T. Okamoto, H. Nishino, M. Otagiri, S. Fujii, and H. Maeda Nanomolar quantification and identification of various nitrosothiols by high performance liquid chromatography coupled with flow reactors of metals and Griess reagent J. Biochem. 122 1997 459 466
10. T. Shingu, K. Yamada, N. Hara, K. Moritake, H. Osago, M. Terashima, T. Uemura, T. Yamasaki, and M. Tsuchiya Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells Cancer Res. 63 2003 4044 4047
11. K.A. Hanafy, J.S. Krumenacker, and F. Murad NO, nitrotyrosine, and cyclic GMP in signal transduction Med. Sci. Monit. 7 2001 801 819
12. M. Quintero, N. Mackenzie, and P.A. Brennan Hypoxia-inducible factor 1 (HIF-1) in cancer Eur. J. Surg. Oncol. 30 2004 465 468
13. L.M. Seeber, R.P. Zweemer, R.H. Verheijen, and P.J. van Diest Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management Obstet. Gynecol. Int. 2010 580971
14. L. Molina y Vedia, B. McDonald, B. Reep, B. Brüne, M. Di Silvio, T.R. Billiar, and E.G. Lapetina Nitric oxide-induced S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase inhibits enzymatic activity and increases endogenous ADP-ribosylation J. Biol. Chem. 267 1992 24929 24932
15. G.C. Brown Nitric oxide and mitochondrial respiration Biochim. Biophys. Acta 1411 1999 351 369
16. J.S. Stamler Redox signaling: nitrosylation and related target interactions of nitric oxide Cell 78 1994 931 936
17. C. Stefanelli, C. Pignatti, B. Tantini, I. Stanic, F. Bonavita, C. Muscari, C. Guarnieri, C. Clo, and C.M. Caldarera Nitric oxide can function as either a killer molecule or an antiapoptotic effector in cardiomyocytes Biochim. Biophys. Acta 1450 1999 406 413
18. M.P. Murphy Nitric oxide and cell death Biochim. Biophys. Acta 1411 1999 401 414
19. D.S. Lind, M.I. Kontaridis, P.D. Edwards, M.D. Josephs, L.L. Moldawer, and E.M. Copeland III Nitric oxide contributes to adriamycin's antitumor effect J. Surg. Res. 69 1997 283 287
20. Y. Ishima, F. Yoshida, U. Kragh-Hansen, K. Watanabe, N. Katayama, K. Nakajou, T. Akaike, T. Kai, T. Maruyama, and M. Otagiri Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin Free Radic. Res. 45 2011 1196 1206
21. Y. Ishima, D. Chen, J. Fang, H. Maeda, A. Minomo, U. Kragh-Hansen, T. Kai, T. Maruyama, and M. Otagiri S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects Bioconjug. Chem. 23 2012 264 271
22. P. Wieczorek, P. Sacha, T. Hauschild, M. Zórawski, M. Krawczyk, and E. Tryniszewska Multidrug resistant Acinetobacter baumannii - the role of AdeABC (RND family) efflux pump in resistance to antibiotics Folia Histochem. Cytobiol. 46 2008 257 267
23. H. Nagai, H. Yasuda, Y. Hatachi, D. Xue, T. Sasaki, M. Yamaya, Y. Sakamori, Y. Togashi, K. Masago, I. Ito, Y.H. Kim, T. Mio, and M. Mishima Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO-cGMP signaling in lung adenocarcinoma cells in vitro and in vivo Int. J. Oncol. 41 2012 24 30
24. L.J. Frederiksen, D.R. Siemens, J.P. Heaton, L.R. Maxwell, M.A. Adams, and C.H. Graham Hypoxia induced resistance to doxorubicin in prostate cancer cells is inhibited by low concentrations of glyceryl trinitrate J. Urol. 170 2003 1003 1007
25. D.D. Browning, I.K. Kwon, and R. Wang cGMP-dependent protein kinases as potential targets for colon cancer prevention and treatment Futur. Med. Chem. 2 2010 65 80
26. L.J. Frederiksen, R. Sullivan, L.R. Maxwell, S.K. Macdonald-Goodfellow, M.A. Adams, B.M. Bennett, D.R. Siemens, and C.H. Graham Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling Clin. Cancer Res. 13 2007 2199 2206
27. T.K. Hamilton, N. Hu, K. Kolomitro, E.N. Bell, D.H. Maurice, C.H. Graham, D.R. Siemens, Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer, World J. Urol. (in press), http://dx.doi.org/10. 1007/s00345-012-0848-7.
28. C. Moorthi, R. Manavalan, and K. Kathiresan Nanotherapeutics to overcome conventional cancer chemotherapy limitations J. Pharm. Sci. 14 2011 67 77